Norman Riendeau, PA
Emergency Medicine · Falls Church, VANPI 1275585432
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,104 and has fallen 55.9% since, to $927 in 2025. Among emergency medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 267 payments — averaging $29.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AstraZeneca$793
- Lilly USA, LLC$755
- AbbVie$583
- GSK$469
- Boehringer Ingelheim$386
- plus $3K from 21 others
What the payments were for
- Food & beverage$7,921100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 56 | $1,730 |
| AstraZeneca | 19 | $793 |
| Lilly USA, LLC | 30 | $755 |
| AbbVie | 24 | $583 |
| GSK | 15 | $469 |
| Boehringer Ingelheim | 13 | $386 |
| Amgen(2 entities) | 8 | $365 |
| Merck | 17 | $328 |
| Esperion Therapeutics, Inc. | 9 | $277 |
| E.r. Squibb & Sons, L.L.C. | 4 | $271 |
| Novartis | 15 | $268 |
| Exact Sciences | 9 | $256 |
| Pfizer | 12 | $241 |
| Bayer | 8 | $235 |
| Sanofi-aventis U.S. LLC | 8 | $214 |
| Biohaven Pharmaceuticals, Inc. | 1 | $150 |
| Astellas Pharma US Inc | 4 | $148 |
| Boston Scientific | 2 | $125 |
| Alnylam Pharmaceuticals Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $61 |
| Shield Therapeutics Inc | 2 | $42 |
| Amarin Pharma, Inc. | 1 | $28 |
| Sumitomo Pharma America, Inc. | 1 | $28 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $28 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $26 |
| Johnson & Johnson | 1 | $26 |
| Gilead | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,921 in reported general payments places this provider in the 95th percentile of 1,279 emergency medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $237,904 |
| FarxigaDapagliflozin Propanediol | 135 | $136,507 |
| JardianceEmpagliflozin | 101 | $117,009 |
| EliquisApixaban | 36 | $44,309 |
| RybelsusSemaglutide | 12 | $33,024 |
| JanuviaSitagliptin Phosphate | 23 | $24,724 |
| Tresiba Flextouch U-200Insulin Degludec | 27 | $22,873 |
| XareltoRivaroxaban | 17 | $20,933 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $16,495 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $12,058 |
| Amlodipine-OlmesartanAmlodipine Bes/Olmesartan Med | 130 | $10,496 |
| Atorvastatin Calcium | 464 | $4,561 |
| VytorinEzetimibe/Simvastatin | 12 | $4,472 |
| Rosuvastatin Calcium | 219 | $4,155 |
| Pioglitazone-MetforminPioglitazone Hcl/Metformin Hcl | 26 | $3,280 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,730 | $270,927115 claims |
| AstraZenecaFarxiga | $793 | $136,507135 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $386 | $129,067113 claims |
| PfizerEliquis | $241 | $44,30936 claims |
| MerckJanuvia, Janumet Xr | $328 | $41,21935 claims |
| Johnson & JohnsonXarelto | $26 | $20,93317 claims |
| AbbVieSynthroid | $583 | $75219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,279 emergency medicine providers in Virginia.
Other emergency medicine in Falls Church
- Scott WeirFalls Church$17K
- Michael BoyleFalls Church$1K
- Edward ReadRichmond$402K
- Alex HamidiWilliamsburg$133K
- David BurtCharlottesville$76K
- Marleine ClayMc Lean$71K
- Christopher ThomCharlottesville$52K
- Michelle ClintonRoanoke$42K
- Clarence KongNorfolk$17K
- Fereshteh SaniMc Lean$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.